A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs GM 6 (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms GMAIS
- Sponsors Genervon Biopharmaceuticals
- 01 Aug 2017 Status changed from recruiting to completed.
- 19 Aug 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 19 Aug 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.